Breakthrough Alzheimer updates: UK adaptive platform trial tests repurposed drugs, new phase 2/3 therapies advance, and sleep disruption emerges as a treatable risk factor.
|Videos|February 22, 2021
Looking Closely at the Types of Dementia
Author(s)John J. Miller, MD
Cognitive disorders are varied and complicated, and require a close eye...
Advertisement
John J. Miller, MD, goes over the specifics of dementia and its varied presentations.
Dr Miller is medical director, Brain Health, Exeter, NH; editor in chief, Psychiatric TimesTM; staff psychiatrist, Seacoast Mental Health Center, Exeter, NH; consulting psychiatrist, Exeter Hospital, Exeter, NH; consulting psychiatrist, Insight Meditation Society, Barre, MA.
Advertisement
Related to this article
Sleep disruption fuels Alzheimer risk via apnea, fragmentation, and inflammation; improving consolidated sleep, medication review, and sleep-specialist teamwork may protect cognition.
UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.
Neurocrine launches a phase 2 trial of once-daily NBI-'567, testing a selective muscarinic agonist to boost cognition in mild to moderate Alzheimer disease.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Synapse-Level Mapping Could Reveal How Disrupted Brain Circuits Lead to Psychiatric Disorders
2
FDA Aligns on Key Elements of Phase 3 Study of Zervimesine for Dementia With Lewy Bodies
3
Dementia Pipeline Update: Phase 2 and 3 Developments in Alzheimer Disease and Lewy Body Dementia
4
Daridorexant, Orexin Receptor Agonist, Shows Positive Results in Pediatric Insomnia
5